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(57) ABSTRACT 
Polyamine cationic lipids have been synthesized that have the 
ability to be transported into cells having an active polyamine 
transport system. Accordingly, these lipids may be conju-
gated with various agents and, thereby, act as vectors for 
transporting the agent into the cell aided by the cell's own 
polyamine transport system. A method of delivering an agent 
into a cell includes associating the agent with a polyamine 
cationic lipid selected from compounds 25, 26, 27, 28, their 
pharmaceutically acceptable salts and combinations thereof 
and contacting the cell therewith. 
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LIPOPHILIC POLYAMINES PROVIDING 
ENHANCED INTRACELLULAR DELIVERY 
OF AGENTS BY A POLYAMINE TRANSPORT 
SYSTEM 
RELATED APPLICATION 
2 
the polyamine transporter (PAT) for cellular entry.25-32 Our 
goal was to perform the key crossover experiments needed to 
tie these two fields together. Indeed, understanding how cat-
ionic motifs are transported across the cell membrane is criti-
cal to both enterprises. 
Targeting a specific cellular transporter could provide cell-
selective transfection. For example, rapidly-proliferating 
cancer cells could be targeted via their PAT, which is often 
up-regulated.28 Indeed, the ability to transfect a specific cell 
This application claims priority from provisional applica-
tion Ser. No. 60/915,492, which was filed on May 2, 2007 and 
which is incorporated herein by reference in its entirety. 10 type would have profound impact on a multitude of gene 
therapy strategies. 
FIELD OF THE INVENTION Since many cancer cell lines have active polyamine trans-
porters, it is possible to target these cells using the molecular 
recognition events involved in polyamine import.28 For This invention relates to polyamines and, more specifi-
cally, to lipophilic polyamines effective in entering cells hav-
ing an active polyamine transport system. 
BACKGROUND OF THE INVENTION 
15 example, an anthracene-homospermidine conjugate was 
shown to be 10-30 fold more toxic to B16 melanoma cells 
than to 'normal' melanocytes (Mel-A cells).28 A multitude of 
polyamine structures were previously screened for their high 
PAT selectivity in CHO and CHO-MG cells.28 Several linear 
20 polyamine architectures were identified, which selectively 
targeted the PAT-active CHO cell line over its PAT-inactive 
CHO-MG mutant.25-32 The discovery ofhomospermidine, a 
4,4-triamine, as a cell-selective 'vector' motif provided the 
means to test the PAT-delivery system as a conduit for gene 
With the information gained by the sequencing of the 
human genome, 1•2 gene therapy now holds promise for the 
treatment of hereditary diseases and cancers.3•4 It is now 
possible to silence a bad gene5, tum on a needed gene6, or 
install a new gene to address particular cellular defects.7 
However, a key requirement for successful gene therapy is the 
efficient transfer of DNA to specific cell types in vivo. Viral 
vectors have proven to be very efficient transfection agents 
and allow for the insertion of foreign DNA into many cell 
types.8·9 However, the inherent problems with viral vectors 
such as immunogenicity and the limited size of the DNA 
plasmid that can be transferred has led to interest in develop-
ing efficient non-viral vectors. 10- 14 Non-viral vectors are 
ideal because of their expected low toxicity and immunoge-
nicity, ability to transfer large strands of DNA and simpler 
synthetic preparation. Typically, these vectors consist of a 35 
lipophilic component attached to a positively charged, polar 
headgroup, through the use of a spacer or linking motif, and 
are a mixture of neutral and positively charged lipids. A wide 
range of cationic liposomes have been synthesized and 
recently reviewed. 15-17 The cationic headgroups typically 40 
found in these liposome systems include quaternary ammo-
nium salts, 10 polylysine, 18 polyguanadinium salts, 19 pol-
yarginine20 and polyamines.21 
25 delivery.26•28 
In short, our aim was to combine these two areas of 
research (PAT targeting and gene delivery) by attaching PAT-
targeting polyamine sequences28 to aryl lipid motif 324 in 
order to facilitate DNA plasmid uptake. These materials were 
30 then evaluated for their DNA-transporting ability as well as 
transfection efficacy and compared to the commercially-
available transfection reagent, Lipofectamine 2000.33 
Polyamines were introduced into liposomes by Behr,22 
when it was realized that the naturally-occurring polyamines 45 
such as spermidine and spermine (FIG. 1) could efficiently 
compact DNA. Behr went on to synthesize one of the first 
transfection vectors, DOGS 1, and incorporated a branched 
polyamine as the polar headgroup (FIG. 2). 11 
Following this work, a number of research groups have 50 
looked at the effect of changing the positively-charged, 
polyamine headgroup on cationic liposomes with respect to 
their efficiency at transfecting DNA. 15·16·21 ·23 ·24 Byk et al21 
showed that when assayed in HeLa cells, the compound RPR 
120535 2, whose configuration of the polar head is linear, was 55 
5-10 times more effective at transfection than those with 
branched-, globular- or T-shaped polar domains. Safinya et 
al24 demonstrated with 3 that lipids containing a higher num-
ber of positive charges had better transfection efficiency 
within a series of liposomes containing branched-polyamine 60 
headgroups. Other popular vectors 4-6 are shown in FIG. 2. 
Commercially-available Lipofectamine is a 3: 1 mixture of 4 
and 6. 186 
Although a large number of cationic lipids have been sur-
veyed, a systematic study of how linear polyamine architec- 65 
tures effect transfection efficiency is still needed, especially 
in light of the molecular recognition elements required to use 
SUMMARY OF THE INVENTION 
With the foregoing in mind, the present invention advan-
tageously provides a vector effective in delivering an agent 
into a cell, said vector comprises a cationic lipid selected from 
compounds according to formulas 25, 26, 27, 28, their phar-
maceutically acceptable salts and combinations thereof. 
Another embodiment of the invention includes a 
polyamine cationic lipid vector effective in delivering an 
agent into a cell in enhanced levels by being recognized by the 
cell's polyamine transport system, said vector comprises 
compound 26 or a pharmaceutically acceptable salt thereof. 
A preferred method of the invention includes delivering an 
agent into a cell, the method comprises associating the agent 
with a polyamine cationic lipid selected from compounds 25, 
26, 27, 28, their pharmaceutically acceptable salts and com-
binations thereof and contacting the cell therewith. 
A further method of the invention includes delivering 
enhanced levels of an agent into a cell, the method comprises 
associating the agent with a polyamine cationic lipid accord-
ing to compound 26 or a pharmaceutically acceptable salt 
thereof and effective in being recognized by a polyamine 
transport system in the cell. 
The invention also includes a method of delivering 
enhanced levels of an agent into target cells having an upregu-
lated polyamine transporter, the target cells being among a 
population of normal cells, the method comprises associating 
the agent with a polyamine cationic lipid according to com-
pound 26 or a pharmaceutically acceptable salt thereof and 
contacting the cell population therewith so as to preferentially 
deliver the polynucleotide into the target cells via the upregu-
lated polyamine transporter system. 
Yet another method of the invention is for treating a target 
cell having an upregulated polyamine transporter, the method 
US 7,910,363 Bl 
3 
comprises associating an agent with a polyamine cationic 
lipid according to compound 26 or a pharmaceutically 
acceptable salt thereof and contacting the cell therewith. 
4 
channel to determine the percentage of cells that expressed 
significant levels of GFP as compared with cells incubated 
with DNA plasmid only; a gate was set just above the thresh-
old measured with no DNA plasmid and no conjugate added 
BRIEF DESCRIPTION OF THE DRAWINGS 
Some of the features, advantages, and benefits of the 
present invention having been stated, others will become 
apparent as the description proceeds when taken in conjunc-
tion with the accompanying drawings, presented for solely 
for exemplary purposes and not with intent to limit the inven-
tion thereto, and in which: 
5 (almost negligible); all cells which exhibited a fluorescence 
signal above that level were considered positive; data are 
presented as the mean±SD; and 
FIG. 1 shows naturally occurring polyamines, as known in 
the prior art; 
FIG. 12 shows [14C]Spermine uptake inhibition by 26; 
tetraamine 26 is an efficient inhibitor of polyamine uptake; 
1° CHO-Kl cells were incubated with 1 µM [14C]spermine (31 
Ci/mo!) for 20 min in serum free medium supplemented with 
varying concentrations of tetraamine 26 as indicated in the 
figure; after extensive rinsing, imported [1 4C]spermine was 
FIG. 2 illustrates additional previously known polyamines; 
FIG. 3 is a diagram of synthetic scheme 1 of the present 
invention; 
15 determined by scintillation counting on cell lysates. 
FIG. 4 diagrams synthetic scheme 2 of the present inven-
tion; 
FIG. 5 shows the flow of synthetic scheme 3 of the present 20 
invention; 
FIG. 6 shows synthetic scheme 4 of the present invention; 
FIG. 7 depicts scheme 5, a final step in the present inven-
tion to produce the desired lipid-polyamine conjugates by 
acidification of the amines with a solution of anhydrous HCI 25 
in ethyl acetate; 
FIG. 8 shows DNA uptake activity by novel cationic lipids 
22-28 (compared with Lipofectamine, LFA). CHO Kl cells 
were grown to confluence in 24-well plates, rinsed with 
medium and incubated for 4 h at 3 7° C. with 1 µg/mL Alexa 30 
Fluor-488-DNA complexed with 0.5 µg/mL (white bars), 2.5 
µg/mL (gray bars), or 5 µg/mL (black bars) of the respective 
cationic lipid, as indicated above each entry; cells were then 
extensively washed with PBS, treated with trypsin, and cell 
pellets were again extensively washed with PBS 1 % BSA to 35 
completely remove non-specific fluorescence from the cell 
exterior; finally, cells were analyzed for Alexa Fluor-488-
DNA uptake by flow cytometry on a FACSCalibur (BD Bio-
sciences) operated by Cell-Quest software. (*) during this 
relatively short incubation (4 h), cells remained viable with 40 
28; note: in converting from µg/mL to µM, the concentrations 
used were typically approximately 0.6, 3 .0, and 6 µM, respec-
tively; 
FIG. 9 shows the results obtained from the experiment 
described by FIG. 8, which were analyzed using a gated 45 
channel to determine the percentage of cells that had inter-
nalized significant amounts of DNA as compared with cells 
incubated with DNA only; a gate was set just above the 
threshold signal for control cells (DNA only with no lipid 
conjugate); note: Alexa Fluor-488-DNA complexed with 0.5 50 
µg/mL (white bars), 2.5 µg/mL (gray bars), or 5 µg/mL (black 
bars) of the respective cationic lipid was used, as indicated in 
FIG. 8; data are presented as the mean±SD. 
FIG. 10 illustrates GFP expression results from transfec-
tion experiments; CHO Kl cells were grown to approxi- 55 
mately 50% sub-confluence in 24-well plates, rinsed with 
medium and incubated for 4 hat 37° C. with 1 µg/mL eGFP 
DNA plasmid complexed with 0.5 µg/mL (white bars), 2.5 
g/mL (gray bars), or 5 µg/mL (black bars) of the respective 
cationic lipid, as indicated above. Medium was then changed, 60 
and cells were incubated for another 24 h to allow for GFP 
DETAILED DESCRIPTION OF PREFERRED 
EMBODIMENTS 
The present invention will now be described more fully 
hereinafter with reference to the accompanying drawings, in 
which preferred embodiments of the invention are shown. 
Unless otherwise defined, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which this invention 
pertains. Although methods and materials similar or equiva-
lent to those described herein can be used in the practice or 
testing of the present invention, suitable methods and mate-
rials are described below. Any publications, patent applica-
tions, patents, or other references mentioned herein are incor-
porated by reference in their entirety. In case of conflict, the 
present specification, including any definitions, will control. 
In addition, the materials, methods and examples given are 
illustrative in nature only and not intended to be limiting. 
Accordingly, this invention may, however, be embodied in 
many different forms and should not be construed as limited 
to the illustrated embodiments set forth herein. Rather, these 
illustrated embodiments are provided so that this disclosure 
will be thorough and complete, and will fully convey the 
scope of the invention to those skilled in the art. Other fea-
tures and advantages of the invention will be apparent from 
the following detailed description, and from the claims. 
As used herein, the term "pharmaceutically acceptable salt 
or prodrug" is intended to describe any pharmaceutically 
acceptable form (such as a salt of these amine systems with an 
organic carboxylic acid like acetic acid or toluene-sulfonic 
acid or methane sulfonic acid or an inorganic acid such as 
HCI, HBr, phosphoric acid, or a related group or prodrug) of 
a compound of the invention, which, upon administration to a 
subject, provides the mature or base compound (e.g., the 
lipophilic polyamine compound). Pharmaceutically accept-
able salts include those derived from pharmaceutically 
acceptable inorganic ororganic bases and acids. Suitable salts 
include those derived from alkali metals such as potassium 
and sodium, alkaline earth metals such as calcium and mag-
nesium, among numerous other acids well known in the phar-
maceutical art. Pharmaceutically acceptable prodrugs refer to 
a compound that is metabolized, for example hydrolyzed or 
oxidized, in the host to form the compound of the present 
invention. Typical examples of prodrugs include compounds 
that have biologically labile protecting groups on a functional 
moiety of the active compound. Prodrugs include compounds 
that can be oxidized, reduced, aminated, deaminated, 
plasmid expression; cells were detached by trypsin treatment 
and analyzed for GFP expression by FACS; Lipofectamine is 
denoted as LFA; the value obtained with DNA plasmid only 
was subtracted from each entry above (almost negligible); 
FIG. 11 shows the results obtained from the experiment 
described in FIG. 10, which were analyzed using a gated 
65 hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, 
alkylated, dealkylated, acylated, deacylated, phosphorylated, 
dephosphorylated to produce the active compound. 
US 7,910,363 Bl 
Results and Discussion 
Synthesis. 
5 6 
could be tolerated by the cell line. Ideally, one would use a 
dose of the conjugate, which is not cytotoxic to the cell line to 
be transfected. This is an important caveat in evaluating DNA 
delivery systems. 
A series of derivatives were synthesized with a variety of 
linear polyamine headgroups. These cationic headgroups 
contained from two to four positive charges. The convergent 5 
synthetic route involved: a) the synthesis of the hydrophobic 
lipid moiety, b) the synthesis of the BOC-protected amine 
head groups, c) coupling of the two separate components 
followed by d) the deprotection of the polyamine moiety to 
furnish the final compounds as HCl salts. 
The 3,4-disubstituted benzene containing lipids were cho-
sen due to the significant success of these lipids in earlier 
transfection studies by Safinya and others. 10023024 This struc-
tural element is also present in DOSPA 4 and DOTMA 5 
(FIG. 2). The unsaturated unit within the ClS chain was 15 
shown to prevent side chain recrystallisation and conferred a 
high degree of flexibility upon the cationic liposomes. These 
side chains were attached to the central benzene core via ether 
linkages. An aldehyde or acid chloride in position 1 allowed 
for attachment of the polyamine component. The polyamine 20 
scaffolds and controls were identified in earlier investigations 
As expected, there were significant differences in the aque-
ous solubility of these new conjugates. DMSO was added in 
portions to provide aqueous solutions of22-2S. Since DMSO 
itself is toxic to CHO cells above 40 µM, stock solutions of 
each conjugate were made in such a manner so that the total 
10 DMSO concentration remained below 40 µM. This constraint 
limited the amount of conjugate that could be dosed. Poorly-
soluble materials required higher DMSO levels, which in tum 
limited the amount of material that could be dosed to cells in 
of PAT-mediated drug delivery.25- 29 
The first step was the synthesis of3,4-di(oleyloxy)benzal-
dehyde Sa by the 0-alkylation of 3,4-dihydroxy benzalde-
hyde 7a with oleyl bromide (Scheme 1 as shown in FIG. 3). 25 
Similarly, the bis-0-alkylation of ethyl 3,4-dihydroxyben-
zoate 7b with oleyl bromide was used to form ethyl 3,4-di 
( oleyloxy)benzoate Sb using the method ofSafinya et al., 23 •24 
Subsequent cleavage of Sb with KOH was carried out to give 
the acid Sc (Scheme 1) followed by treatment with oxalyl 30 
chloride to give the desired acid chloride Sd. 
As shown in Scheme 2 (FIG. 4), the next step in the syn-
thesis involved the generation of the polyamine moieties: 
N 1 -( tert-butoxycarbony 1) putrescine 9, N 1 ,N4 -di-( tert-bu-
toxycarbony l) homospermidine 1234 and N 1 ,N4 ,N8-tri-(tert- 35 
butoxycarbonyl) homospermine 14 (Scheme 2). The mono 
BOC protection of diaminobutane gave the amine 9 in a good 
yield. Sequential addition of bromobutyronitrile, BOC pro-
tection of the newly formed secondary amine, followed by 
reduction of the nitrile with Raney Ni gave masked triamine 40 
12. Repetition of these three steps on 12 gave tri-BOC-pro-
tected tetraamine 14. 
The coupling of the aldehyde Sa to a range of polyamines 
was based on previous procedures for coupling of amines to 
benzaldehydederivatives.25 -28 As showninScheme3 (shown 45 
in FIG. 5), the reductive amination of Sa was achieved in two 
steps via in situ generation of the imine (with a series of 
amines) followed by reduction using NaBH4 to give the 
respective 2° amines (15-19). As shown in Scheme 4 (shown 
in FIG. 6), therespectivepolyamines 12 and 14 were coupled 50 
to acid chloride Sd to provide the BOC-protected benzamide 
systems, 20 and 21. 
The final step to produce the desired lipid-polyamine con-
jugates involved acidification of the amines with a solution of 
anhydrous HCl in ethyl acetate. 23024 As shown in Scheme 5 55 
(shown in FIG. 7), treatment of the penultimate compounds 
15-21 with anhydrous HCl/EtOAc provided the target HCl 
salts, 22-2S. By design, the lipid portion of the conjugate 
(boxed structure in Scheme 5) was held constant throughout 
the series. This feature allowed for later comparisons and an 60 
understanding of how the polyamine component influenced 
DNA delivery. 
Biological Evaluation. 
Before conducting the transfection studies, the series of 
conjugates (22-2S) were first evaluated for cytotoxicity in 65 
Chinese Hamster Ovary (CHO) cells. This was an important 
step in determining what dose of lipid-polyamine conjugate 
our toxicity screen. 
Taking these factors into account, cytotoxicity screens 
were performed to investigate the relative toxicity of each 
system. Most materials were relatively non-toxic with IC50 
values ~20 µM. Armed with this insight, cells were treated 
with ~6.4 µM of the polyamine conjugate so as to avoid 
significant toxic effects from the delivery agent itself. Indeed, 
at this dose ~90% of cells survived transfection for all com-
pounds except 2S. Indeed, compound 2S was very toxic (after 
24 h incubation) and even at the lowest dose used for trans-
fection (0.5 µg/mL; 0.5 µM 2S) killed 95% of the cells. As 
such, 2S was too toxic for efficient transfection at the doses 
surveyed and its data is strongly biased by the few remaining 
cells, which survived. 
Gene Transfer Studies. 
Armed with knowledge of the cytotoxicity range of the 
series 22-2S, CHO-Kl cells were evaluated for DNA uptake 
using a fluorescently labeled DNA Alexa Fluor-4SS-DNA). 
As shown in FIG. 8, cells were dosed with the Alexa Fluor-
4SS-DNA in the presence of increasing concentrations (i.e., 
0.5, 2.5, 5 µg/mL) of the respective conjugate, 22-2S. Each 
conjugate was as good (24, 25) or better (26, 27) than the 
lipofectamine control (LFA, except 22 and 23) and facilitated 
uptake of the fluorescent DNA probe in a concentration-
dependent manner (µg/mL). 
While the molecular weights in this series do range from 
7S4 (22), S40 (23), S44 (24), S91 (25), 999 (26), S69 (27), and 
976 g/mol (2S), they are relatively close (within 10-22%) and 
allow for general comparisons, especially in light of the large 
differences observed in activity. For example, tetraamine 26, 
which has the highest molecular weight of the series (999 
g/mol), was at a slightly lower concentration (5 µM) than 22 
(6.4 µM) at the 5 µg/mL dose. Nevertheless, DNA uptake 
experiments with tetraamine 26 had over a 5-fold increase in 
DNA uptake (as measured by fluorescence of the imported 
DNA probe) than those conducted with diamine 22. Clearly, 
compound 26 was more efficient in facilitating DNA delivery 
to cells. 
Interestingly, conjugate 27, which represents a butanedi-
amine motif similar to 22 except with the diamine placed 
further away from the lipid tail, was a more efficient DNA 
delivery agent than 22. In contrast, compound 23, which 
separated the ammonium centers via an octanediamine had 
similar or lower activity as 22 (depending on the dose). Inser-
tion of the polyether motif present in 24 maintained this 
eight-atom spacer, yet nearly doubled the DNA delivery 
(DNA probe fluorescence) observed. 
The PAT-selective homospermidine motif present in 25 
resulted in a three-fold increase in DNA delivery. However, 
this outcome may simply be due to the presence of the addi-
tional charge provided by the triamine motif present in 25. 
Indeed, significant increases in DNA delivery were observed 
US 7,910,363 Bl 
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across the homologous series 22, 25, and26 which at 5 µg/mL 
gave 94, 281 and 504 fluorescence absorbance units (a.u.), 
respectively. 
8 
percentage of cells that expressed significant levels ofGFP as 
compared with cells incubated with DNA plasmid only. A 
gate was set just above the threshold measured with no DNA 
FIG. 8. shows DNA uptake activity by novel cationic lipids 
22-28 (compared with Lipofectamine, LFA). CHO Kl cells 5 
were grown to confluence in 24-well plates, rinsed with 
medium and incubated for 4 h at 3 7° C. with 1 µg/mL Alexa 
Fluor-488-DNA complexed with 0.5 µg/mL (white bars), 2.5 
µg/mL (grey bars), or 5 µg/mL (black bars) of the respective 
cationic lipid, as indicated above each entry. Cells were then 10 
extensively washed with PBS, treated with trypsin, and cell 
pellets were again extensively washed with PBS 1 % BSA to 
completely remove non-specific fluorescence from the cell 
exterior. Finally, cells were analyzed for Alexa Fluor-488-
DNA uptake by flow cytometry on a FACSCalibur (BD Bio- 15 
sciences) operated by Cell-Quest software. (*) during this 
relatively short incubation (4 h), cells remained viable with 
28. Note: in converting from µg/mL to µM, the concentrations 
used were typically approximately 0.6, 3 .0, and 6 µM, respec-
tively and are tabulated specifically in the Supporting infor- 20 
plasmid and no conjugate added (almost negligible). All cells 
which exhibited a fluorescence signal above that level were 
considered positive. Data are presented as the mean±SD. 
These are shown in FIG. 11. 
The interpretation of the data in FIGS. 10 and 11 can be 
quite subtle. For example, FIG. 10 relates the amount ofGFP 
expression per cell and is a summary measurement of how 
well the DNA 'message' was delivered, read and protein 
(GFP) produced. While the magnitudes are different the rela-
tive trends are consistent with those observed in FIG. 8. In this 
regard, DNA delivery correlated with GFP expression. 
FIG. 11 revealed the% GFP positive cells observed in the 
total cell population after the transfection experiment. This 
information is a direct measure of transfection efficiency. 
Using the 5 µg/mL dose for comparisons, 22 (38%), 25 
(49%), and27 (40%) were all comparable to the LFA control 
( 41 % ) in terms of transfection efficiency. Both 23 (23%) and 
24 (25%) gave lower values. The lone standout was tet-mation. 
In FIG. 9 we see the results obtained from the experiment 
described by FIG. 8, which were analyzed using a gated 
channel to determine the percentage of cells that had inter-
nalized significant amounts of DNA as compared with cells 
incubated with DNA only. A gate was set just above the 
threshold signal for control cells (DNA only with no lipid 
conjugate). Note: Alexa Fluor-488-DNA complexed with 0.5 
µg/mL (white bars), 2.5 µg/mL (grey bars), or 5 µg/mL (black 
bars) of the respective cationic lipid was used, as indicated in 
FIG. 8. Data are presented as the mean±SD. 
While the average amount of DNA taken up/cell shows 
wide variations between the different compounds (FIG. 8), all 
compounds were able to deliver significant amounts of DNA 
to virtually the entire cell population (FIG. 9). However, in 
terms of gene therapy, simple DNA delivery to the cell is 
insufficient. There are other cellular barriers, which must be 
traversed. 
GFP Expression Studies. 
In order for the 'therapy' to be effective, the DNA must 
escape from the endosome and enter the cell's nucleus, be 
transcribed to a regulatory, non coding RNA (RNAi) or to 
mRNA that is translated into its coded protein. Therefore, we 
investigated the conjugate-assisted expression of an eGFP 
DNA plasmid encoding for the green fluorescent protein 
(GFP). CHO cells, which were successfully transfected, were 
easily identified by their green fluorescence. Control experi-
ments conducted with only the eGFP DNA plasmid (and no 
lipid carrier) gave virtually no fluorescence. A gate or instru-
mental threshold was set based upon this low background 
fluorescence. Fluorescence detected above this background 
was considered a positive response. 
FIG. 10. GFP Expression Results from Transfection Experi-
ments. 
CHO Kl cells were grown to approx. 50% sub-confluence 
in 24-well plates, rinsed with medium and incubated for 4 hat 
37° C. with 1 µg/mL eGFP DNA plasmid complexed with 0.5 
µg/mL (white bars), 2.5 µg/mL (grey bars), or 5 µg/mL (black 
bars) of the respective cationic lipid, as indicated above. 
Medium was then changed, and cells were incubated for 
another 24 h to allow for GFP plasmid expression. Cells were 
detached by trypsin treatment and analyzed for GFP expres-
sion by FACS. Lipofectamine is denoted as LFA. The value 
obtained with DNA plasmid only was subtracted from each 
entry above (almost negligible). 
The results obtained from the experiment described in FIG. 
10 were analyzed using a gated channel to determine the 
raamine 26 (67%), which had over 50% higher transfection 
efficiency than the LFA control ( 41 % ). 
Cells treated with conjugate 23 at the high dose (5 µg/mL, 
25 black bars in FIG. 9) gave 84% positive cells of the total cell 
population remaining after the DNA uptake experiment; 
whereas all the others (LFA, 22, and 24-28) gave typically 
>94% positive cells. Using these data as benchmarks of DNA 
import via each conjugate, the significantly lower % GFP 
30 positive cells (23-67%) observed in FIG. 11 suggests that 
intracellular processing and nuclear delivery of DNA also 
depend on the structure of the cationic lipid. 
A closer analysis of the data revealed just how important 
these latter two parameters (i.e., intracellular processing and 
35 nuclear delivery) are for successful gene delivery. For 
example, although 26 was capable of delivering 3-fold more 
DNA to the cell than the control LFA (black bars in FIG. 8: 26: 
504; LFA: 158 a.u.), the relative GFP expression/cell was 
only two fold higher in FIG. 10 (25 vs. 13 a.u.) and the% of 
40 GFP positive cells was only 1.5 fold higher in FIG. 11 (67% 
vs.41%). 
It cannot be excluded that maximum GFP expression 
occurs at varying time points post-transfection for the differ-
ent compounds. Nevertheless, the data reflect an interesting 
45 correlation between intracellular processing of internalized 
DNA and the cationic lipid structure. 
In summary, while a significant number of cells imported 
the fluorescent DNA probe in the presence of the synthetic 
conjugates (22-28), the amount of the DNA probe entering 
50 each cell varied depending upon the conjugate used. The % 
GFP positive cells of the total cell population roughly corre-
lated with the GFP expression/cell. Cells with low % GFP 
positive cells (FIG. 11: 23, 23%; 24, 25%) had low GFP 
expression/cell (FIG.10: 23, 5; 24, 7). Cells with high% GFP 
55 positive cells (FIG. 11: 26, 67%) had high GFP expression/ 
cell (FIG. 10: 26, 25). Indeed, the additional 'intracellular 
barriers' associated with successful GFP expression (as 
shown in FIG. 11 in terms of% GFP positive cells) seemed to 
moderate the large differences seen in the earlier DNA deliv-
60 ery study (FIG. 8). 
We theorized that 26 may be using the polyamine trans-
porter, PAT, for cellular entry. Indeed, as shown in FIG. 12, 
tetraamine 26 was shown to be a potent inhibitor of spermine 
uptake (IC50 of approximately 10 µM) using a 14C-radiola-
65 beled spermine competition assay. This observation implied 
that 26 was able to compete for the polyamine recognition 
sites on the cell surface (e.g., PAT). Therefore, it is possible 
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that certain lipophilic polyamines, which present the correct 
polyamine 'message', may be able to recognize and target 
cells expressing high levels of polyamine transporters on their 
cell surface (e.g., cancer cells, rapidly dividing tumors, etc.). 
However, as shown in this report, delivery into the cell is just 5 
one step in successful gene transfection. Nevertheless, the 
findings disclosed herein are an important first step in devel-
oping 'smart' transfection agents. 
Proof-of-principle for this novel therapeutic approach was 
provided in the following journal article which utilized an 10 
anti-cancer toxin that consisted of a chemical conjugate 
between the human urokinase plasminogen activator and 
saporin: Lipopolyamine Treatment Increases the Efficacy of 
Intoxication with Saporin and an Anticancer Saporin Con ju- 15 
gate. Geden S. E.; Gardner R. A.; Fabbrini M. S.; Ohashi M.; 
Phanstiel, IV, O.; Teter K. FEES J. 2007, 274, 4825-4836 
(published onlineAug. 22, 2007). This journal article is incor-
porated herein by reference in its entirety. 
We have also documented lipopolyamine-induced toxin 20 
sensitization with two other saporin-based toxins: (i) FGF-
saporin, a chemical conjugate between fibroblast growth fac-
tor and saporin; and (ii) the OKTlO immunotoxin which 
consists of a chemical conjugate between saporin and an 
antibody that recognizes the CD38 cancer antigen. DU145 25 
human prostate cancer cells exposed to lipopolyamine 26 and 
FGF-saporin were 85-fold more sensitive to intoxication than 
cells incubated with FGF-saporin alone. The commercial 
transfection agent Lipofectamine generated significant cellu-
lar sensitization to FGF-saporin as well. However, Lipa- 30 
fectamine also sensitized a non-target cell population (HeLa 
cells, which do not express the FGF receptor) to FGF-saporin. 
In contrast, HeLa cells exposed to lipopolyamine 26 and 
FGF-saporin were no more sensitive to intoxication than cells 
incubated with FGF-saporin alone. Our reagent thus exhib- 35 
ited a level of specificity that was not seen with Lipo-
fectamine. We have also shown that Ramos human leukemia 
cells exposed to lipopolyamine 26 and OKTlO are 100-fold 
more sensitive to intoxication than cells incubated with 
OKTlO alone. Ramos cells exposed to Lipofectamine and 40 
OKTlO were no more sensitive to intoxication than cells 
exposed to OKTlO alone. Collectively, these results demon-
strate the utility of our lipopolyamine compounds over the 
commercially available Lipofectamine reagent. 
10 
only slightly higher transfection efficiency than 22 (e.g., 25 
and 22 gave 49% and 38% GFP positive cells in FIG. 11, 
respectively). 
This phenomenon was also observed with the two 
diamines, 27 and 22. Compound 27 showed greater than 
4-fold enliancement in DNA delivery over its butanediamine 
analogue 22. Evidently, moving the diamine 'message' fur-
ther away from the lipid component enlianced the delivery 
characteristics of the conjugate (FIG. 8). Again, this potential 
delivery enliancement by 27 was tempered by the latter steps 
of the transfection process. Alas, nearly identical transfection 
efficiency was observed for 27 and 22 ( 40% and 38% GFP 
positive cells in FIG. 11, respectively). 
Clearly, cellular DNA delivery alone is insufficient for 
successful transfection. Understanding how different 
polyamine structures21 ' 36 and neutral lipids like 635 enliance 
the intracellular trafficking and nuclear delivery of plasmid 
DNA is critical for the future design of efficient polyamine 
transfection agents. 
Experimental. 
Materials. 
Silica gel (32-63 µm) and chemical reagents were pur-
chased from commercial sources and used without further 
purification. All solvents were distilled prior to use. 1 H and 
13C NMR spectra were recorded at 300 and 75 MHz, respec-
tively, unless otherwise noted. TLC solvent systems are based 
on volume % and NH40H refers to concentrated aqueous 
NH4 0H. High-resolution mass spectrometry was performed 
at the University of Florida Mass Spectrometry facility. 
Materials and Methods 
ULYSISAlexaFluor-488 (Molecular Probes) was used for 
labeling of DNA as recommended by the manufacturer. All 
fine chemicals were from Sigma. Lipofectamine 2000 was 
purchased from Invitrogen. Wild-type Chinese hamster ovary 
cells (CHO-Kl) were obtained from the ATCC (Manassas, 
Va., USA). CH 0 cells were routinely cultured in F 12K nutri-
ent mixture supplemented with 10% (v/v) fetal calf serum, 2 
mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml 
streptomycin (growth medium) in a humidified 5% C02 , 37° 
C. incubator. 
DNA uptake studies. AlexaFluor-488 labeled DNA with or 
without cationic lipid was mixed in serum-free F12K and 
added to extensively rinsed cells grown in 24-well plates. 
Cells were then incubated for 4 hat 37° C. After removal of 
Conclusions. 45 the incubation medium and rinsing with PBS, cells were 
detached with trypsin followed by extensive washing with 
ice-cold PBS, 1 % (w/v) bovine serum albumin (BSA) to 
remove non-specific fluorescence. Finally, cells were sus-
This investigation demonstrated that the number and posi-
tion of the positive charges along the polyamine scaffold 
plays a key role in DNA delivery and in determining the 
intracellular outcome of the DNA import event, i.e. the trans-
fection efficiency. Although the Lipofectamine (LFA: 75% 4 50 
and 25% 6 mixture) has five positive charges (presumably a 
DNA delivery enliancing feature) in one of its components 
(e.g., 4), it also has a neutral component DOPE 6 present, 
which makes structural comparisons to this control difficult 
beyond the dose to dose comparisons made above. Future 55 
studies will look at the effect of neutral lipids (like 6) in terms 
of transfection efficiency of polyamine-lipid conjugates. 
Indeed, DOPE 6 has been shown to play a role in endosome 
disruption and to facilitate transfection.35 
In addition, this paper presented the first study, which probed 60 
the transfection phenomena with a PAT-selective homosper-
midine motif28 attached to a lipid cargo, e.g., 25. As expected 
compound 25 showed a 3-fold enliancement in DNA delivery 
over its butanediamine analogue 22. Unfortunately, the DNA 
delivery enliancement observed with 25 seemed to be muted 65 
by the latter steps of the transfection process (e.g., intracel-
lular trafficking, nuclear delivery, etc). As a result, 25 had 
pended in PBS, 1 % BSA and analyzed for DNA uptake by 
flow cytometry on a FACSCalibur (BD Biosciences) operated 
by Cell-Quest software. Cells remained viable with all com-
pounds tested, including 28. 
GFP transfection experiments---eGFP encoding DNA 
plasmid with or without cationic lipid was mixed in F 12K and 
incubated with pre-rinsed, sub-confluent cells in 24-well 
plates for 4 h, followed by another incubation period of 24 h 
in growth medium. Cells were then washed with PBS, 
detached by trypsin treatment, dissolved in PBS, 1 % BSA, 
and analyzed by FACS for GFP expression. Note: severe 
toxicity was noted for compound 28 after the 24 h incubation 
period. 
Biological Studies. 
CHO cells were grown in RPMI medium supplemented 
with 10% fetal calf serum, glutamine (2 mM), penicillin (100 
U/mL), streptomycin (50 µg/mL). Cells were grown at 37° C. 
under a humidified 5% C02 atmosphere. Aminoguanidine (2 
mM) was added to the culture medium to prevent oxidation of 
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the drugs by the enzyme (bovine serum amine oxidase) 
present in calf serum. Trypan blue staining was used to deter-
mine cell viability before the initiation of a cytotoxicity 
experiment. L1210 cells in early to mid log-phase were used. 
Cell growth was assayed in sterile 96-well microtiter plates 5 
(Becton-Dickinson, Oxnard, Calif., USA). CHO cells were 
plated at 2e3 cells/mL. Drug solutions (10 µL per well) of 
appropriate concentration were added after an overnight 
incubation for the CHO cells. After exposure to the drug for 
4S hr, cell growth was determined by measuring formazan 10 
formation from 3-( 4,5-dimethylthiazol-2-yl)2,5-diphenyltet-
razolium using a Titertek Multiskan MCC/340 microplate 
reader for absorbance (540 nm) measurements.37 These 
experiments allowed for a quick assessment of conjugate 15 
cytotoxicity and facilitated determination of the proper dos-
ing for the latter transfection and delivery experiments. 
3,4-Bis-octadec-9-enyloxy-benzaldehyde (Sa): 
To a solution of oleyl bromide (1.S g, 5.4 mmol) in cyclo-
hexanone (20 ml) was added protocatachualdehyde (0.341 g, 20 
2.5 mmol), potassium carbonate (1.02 g, 7.4 mmol) and 
potassium iodide (0.05 g, 0.3 mmol). The suspension was 
stirred at 100° C. for 1 S hours under nitrogen. Due to the light 
sensitivity of the oleyl bromide the flask was covered in 
aluminum foil. TLC (10% MeOH/CHCl3 ) showed the reac- 25 
tion was complete. The hot reaction mixture was filtered to 
remove some of the particulates and the solvent was removed 
12 
Acid chloride (Sd): 
See Compound 20 for experimental details. 
( 4-Amino-butyl)-carbamic acid tert-butyl ester (9): 
1,4-Diaminobutane (4.4 g, 0.05 mo!) was dissolved in a 
solution oftriethylamine and methanol (10% TEA in MeOH, 
110 mL). A solution of di-tert-butyl dicarbonate (3.63 g, 
0.017 mo!) in methanol (10 mL) was added dropwise to this 
mixture with vigorous stirring. The mixture was stirred at RT 
overnight. The tert-butoxy-carbonylation was complete as 
evidenced by TLC (4% NH40H/MeOH). The excess 1,4-
diaminobutane, methanol and TEA were removed in vacuo to 
yield an oily residue that was dissolved in dichloromethane 
(100 mL) and washed with a solution of sodium carbonate 
(10% aq, 2xlOOmL). The organic layer was dried over anhy-
drous sodium sulfate, filtered, the solvent removed in vacuo 
and the oily residue purified by flash colunm chromatography 
(1:10:S9 NH4 0H:MeOH:CHCl3 ) to give the product 9 as a 
clear oil (2.23 g, 71%), Rf=0.3S (1:10:S9 NH40H:MeOH: 
CHCl3 ). 1HNMR(CDCl3 )d4.72 (brs, lH, NHCO), 3.12 (q, 
2H, CH2 ), 2.70 (t, 2H, CH2), 1.57-1.30 (m, 13H, 2xCH2 , 
3xCH3 ). 
[ 4-(3-Cyano-propylamino )-butyl]-carbamic acid tert-butyl 
ester (10): 
To a solution of the BOC protecteddiamine 9 (2.10 g, 0.01 
mo!) in anhydrous acetonitrile ( 50 mL) was added potassium 
carbonate (5.14 g) and the suspension was stirred at RT for 10 
minutes. A solution of 4-bromobutyronitrile (1.65 g, 0.01 
mo!) in acetonitrile (25 mL) was added and the resulting 
mixture stirred at 50° C. for 24 hours. TLC (1:10:S9 NH4 0H: 
MeOH:CHCl3 ) showed that the reaction was 95% complete. 
The mixture was filtered to remove most of the inorganic salts 
and the acetonitrile was removed in vacuo to give a solid/oily 
residue that was purified by flash colunm chromatography 
(1:5:94 NH4 0H:MeOH:CHCl3 ) to yield the product 10 as a 
clear oil (1.74 g, 61 %), Rf=0.5 (1:10:S9 NH40H:MeOH: 
CHCl3 ); 1HNMR(CDCl3 ) d4.79 (brs, lH, NHCO), 3.12 (q, 
2H, CH2 ), 2.74 (t, 2H, CH2 ), 2.60 (t, 2H, CH2), 2.46 (t, 2H, 
CH2), 1.Sl (quin, 2H, CH2 ) 1.57-1.37 (m, 13H, 2xCH2 , 
3xCH3 ). 
( 4-tert-Butoxycarbony !amino-butyl )-(3-cyano-propyl )-car-
bamic acid tert-butyl ester (11): 
The amino-nitrile 10 (1.74 g, 6.S mmol) was dissolved in a 
solution oftriethylamine and methanol (10% TEA in MeOH, 
40 mL). A solution of di-tert-butyl dicarbonate (3.63 g, 0.017 
in vacuo. The residue was dissolved in CHCl3 (100 mL) and 
washed with water (2x75 mL). The CHCl3 layer was dried 
over anhydrous sodium sulphate, filtered and the solvent 30 
removed in vacuo to give a dark yellow oil. The oily residue 
was purified by flash colunm chromatography (5% EtAc/ 
hexane) to yield the product Sa as a white solid (1.0S g, 69% ), 
Rf=0.3 (5% EtAc/hexane). 1H NMR (CDCl3 ) d 9.SO (s, lH, 35 
CHO), 7.37 (m, 2H,phenyl), 6.93 (d, lH,phenyl), 5.33 (t, 4H, 
olefinic), 4.06 (t, 2H, OCH2 ), 4.04 (t, 2H, OCH2 ), 2.01 (m, 
SH, CH2C=C), 1.S5 (m, 4H, CH2CH2 0), 1.50-1.lS (m, 44H, 
22xCH2 ), O.SS (t, 6H, CH3 ); rrc NMR (CDCl3 ) d 191.00, 
155.34, 149.95, 130.14, 130.12, 129.97, 126.79, 111.S9, 40 
111.04, 69.36, 32.29, 30.16, 29.92, 29.90, 29.SS, 29.72, 
29.64, 29.62, 29.44, 29.36, 27.60, 26.37, 26.34, 23.09, 14.53; 
HRMS (FAB): theory for C43H750 3 (M + 1 ), 639 .5716; found 
(M+l), 639.5755.Anal. (C43H740 3 ): C, H. 
3,4-Bis-octadec-9-enyloxy-benzoic acid (Sc): 
To a solution of oleyl bromide (1.S g, 5.4 mmol) in cyclo-
hexanone (20 ml) was added ethyl 3,4-dihydroxybenzoate 7b 
(0.45 g, 2.5 mmol), potassium carbonate (1.02 g, 7.4 mmol) 
and potassium iodide (0.05 g, 0.3 mmol). The suspension was 
stirred at 100° C. for 1 S hours under nitrogen. Due to the light 50 
sensitivity of the oleyl bromide the flask was covered in 
aluminum foil. The hot reaction mixture was filtered to 
remove some of the particulates and the solvent was removed 
45 mo!) in methanol (20 mL) was added dropwise to this mixture 
with vigorous stirring. The mixture was stirred at it overnight. 
TLC (1:10:S9 NH4 0H:MeOH:CHCl3 ) showed the tert-bu-
toxycarbonylation was complete. The methanol and TEA 
in vacuo. The residue containing ester Sb was dissolved in a 
solution of ethanol (20 mL) containing potassium hydroxide 
(O.S g, 20 mmol) and refluxed for 4 h. The hot reaction 
mixture was added to water (30 mL) and acidifying with IM 
HCI to pH 1 resulted in the precipitation of a white solid. The 
solid Sc was filtered off and washed several times with water. 
The crude acid was re-crystallized from ethanol (10 mL) to 
give the product Sc as a white solid (1.14 g, 70% ); 1 H NMR 
(500 MHz, CDCl3 ) d 7.73 (dd, lH, phenyl), 7.5S (d, lH, 
phenyl), 6.S9 (d, lH, phenyl), 5.35 (t, 4H, olefinic), 4.05 (2xt, 
4H, 2xOCH2 ), 2.01 (m, SH, CH2C=C), 1.S5 (m, 4H, C 
H2 CH20), 1.4S (quin, 4H, 2xCH2 ), 1.41-1.19 (m, 40H, 
20xCH2 ), O.SS (t, 6H, CH3 ). 
were removed in vacuo to yield an oily residue that was 
dissolved in dichloromethane (100 mL) and washed with a 
solution of sodium hydroxide (2.5 M, 3x30 mL) and water 
(2x30 mL). The organic layer was dried over anhydrous 
Na2S04 , filtered, the solvent removed in vacuo and the oily 
residue purified by flash colunm chromatography ( 40% EtAc/ 
55 hexane) to give the product 11 as a clear oil (2.10 g, S7% ), 
Rf=0.45 ( 40% EtAc/hexane ); 1 H NMR (CDCl3 ) d 4.60 (br s, 
lH, NHCO), 3.2S (t, 2H, CH2), 3.14 (m, 4H, 2xCH2), 2.35 (t, 
2H, CH2 ), 1.SS (quin, 2H, CH2 ), 1.5S-1.2S (m, 22H, 2xCH2 , 
6xCH3 ). 
60 ( 4-Amino-butyl)-( 4-tert-butoxycarbonylamino-butyl)-car-
bamic acid tert-butyl ester (12): 
The nitrile 11 (2.00 g, 5.6 mmol) was dissolved in ethanol 
(100 mL). NH4 0H (10 mL) and Raney nickel (S g) were 
added and ammonia gas was bubbled through the solution for 
65 20 minutes at 0° C. The suspension was hydrogenated at 50 
parr for 24 hours. Air was bubbled through the solution and 
the Raney nickel was removed by filtering through a sintered 
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glass funnel keeping the Raney nickel residue moist at all 
times. The ethanol and NH40H were removed in vacuo and 
the oily residue dissolved in CH2Cl2 and washed with 10% 
aq, Na2C03 (3x50 mL). The organic layer was dried over 
anhydrous Na2S04, filtered and the solvent removed in vacuo 5 
to give the product 12 as a clear oil without further purifica-
tion (1.92 g, 95% ), Rf=0.4(1:10:S9 NH40H:MeOH:CHCl3); 
14 
nitrogen overnight. 1 H NMR showed the reaction to be com-
plete when there was no aldehyde peak present. The solvent 
was removed in vacuo and the crude imine dissolved in 
CH2CliMeOH (1:1, 10 mL). The solution was cooled to 0° 
C. and NaBH4 (60 mg, 1.5S mmol) was added in 15 mg 
portions over 30 minutes. TLC (10% EtAc/hexane) showed 
the reaction to be complete after stirring overnight. The sol-
vent was removed in vacuo and the crude oil dissolved in 
CH2Cl2 ( 50 mL) and washed with sodium carbonate (10% aq, 
1H NMR (CDCl3) d 4.65 (br s, lH, NHCO), 3.14 (m, 6H, 
3xCH2), 2.69 (t, 2H, CH2), 2.35 (t, 2H, CH2), 1.5S-1.26 (m, 
26H, 4xCH2, 6xCH3). 
( 4-tert-Butoxycarbonylamino-butyl )-{ 4-[ tert-butoxycarbo-
ny 1-(3-cyano-propy !)-amino ]-buty I }-carbamic acid tert-bu-
ty lester (13): 
1 o 3 x40 mL). The CH2Cl2 layer was dried over N a2C03, filtered, 
the solvent removed in vacuo and the oily residue purified by 
flash colunm chromatography ( 4% MeOH/CHCl3) to give the 
product 15 as a clear oil (O.lS g, 7S%), Rf=0.2 (3% MeOH/ 
CHCl3). 1H NMR (500 MHz, CDCl3) d 6.S5 (s, lH, aryl), 
6.SO (m, 2H, aryl), 5.34 (t, 4H, olefinic), 4.7S (br s, lH, 
NHCO), 3.97 (q, 4H, OCH2), 3.69 (s, 2H, benzylic), 3.13 (m, 
To a solution the amine 12 (1.32 g, 3.6S mmol) in anhy-
drous acetonitrile (20 mL) was added potassium carbonate 15 
(1.7 g) and the suspension was stirred at rt for 10 minutes. A 
solution of 4-bromobutyronitrile (0.54 g, 3.6S mmol) in 
acetonitrile (10 mL) was added and the resulting mixture 
stirred at 50° C. under nitrogen for 24 hours. TLC (1:10:S9 
NH40H:MeOH:CHCl3) showed the reaction was 95% com- 20 
plete. The mixture was filtered to remove most of the inor-
ganic salts and the acetonitrile was removed in vacuo to give 
a solid/oily residue. The oil was dissolved in anhydrous THF 
(70 mL). A solution of di-tert-butyl dicarbonate (1.21 g, 5.5 
mmol) in THF (20 mL) was added dropwise to this mixture 25 
with vigorous stirring. The mixture was stirred at RT over-
night. TLC (1:10:S9 NH40H:MeOH:CHCl3) showed the 
tert-butoxycarbonylation was complete. The THF was 
removed in vacuo to yield an oily residue that was dissolved 
in dichloromethane (100 mL) and washed with a solution of 30 
sodium hydroxide (2.5 M, 3x30 mL). The organic layer was 
dried over anhydrous sodium sulfate, filtered, the solvent 
removed in vacuo and the oily residue purified by flash col-
unm chromatography (CHCl3/MeOH 99: 1) to give the prod-
uct 13 as a clear oil (1.46 g, 75%), Rf=0.5 (CHCl3/MeOH 35 
99:2); 1H NMR (CDCl3) d4.63 (bs, lH, NHCO), 3.2S (t, 2H, 
CH2), 3.14 (m, SH, 4xCH2), 2.64 (t, 2H, CH2), 1.SS (quin, 
2H, CH2), 1.5S-1.35 (m, 35H, 4xCH2, 9xCH3). 
{ 4-[( 4-Amino-butyl)-tert-butoxycarbonyl-amino ]-butyl}-
( 4-tert-butoxycarbonyl-amino-butyl)-carbamic acid tert-bu- 40 
tyl ester (14): 
The nitrile 13 (1.33 g, 2.5 mmol) was dissolved in ethanol 
(100 mL). NH40H (10 mL) and Raney nickel (6 g) were 
added and ammonia gas was bubbled through the solution for 
2H, CH2) 2.63 (t, 2H, CH2NH), 2.01 (m, SH, CH2C=C), 1.SO 
(m, 4H, CH2CH20), 1.55 (m, 4H), 1.49-1.12 (m, 57H, 
24xCH2, 3XCH3), O.S9 (t, 6H, CH3); 13C NMR (CDCl3) d 
156.17, 149.34, 14S.29, 133.15, 130.11, 130.00, 120.67, 
114.lS, 114.0S, 79.23, 69.69, 69.52, 54.12, 49.22, 40.SO, 
32.2S, 30.16, 29.92, 29.S2, 29.71, 29.67, 2S.Sl, 2S.27, 27.6S, 
27.60, 26.44, 23.09, 14.54; Anal. (C52H94N20 4): C, H, N. 
N1 -(3,4-Bis-octadec-9-enyloxy-benzyl)-octane- l ,S-diamine 
(16): 
To a vigorously stirred solution of diaminooctane (0.23 g, 
1.56 mmol, 5 equiv) in CH2CliMeOH (3: 1, 5 mL) was added 
a solution of the aldehyde Sa (0.20 g, 0.33 mmol) in CH2Cl2/ 
MeOH (3:1, 5 mL), dropwise over 1 hour. The resulting 
mixture was stirred at RT under an atmosphere of nitrogen 
overnight. NMR showed the reaction to be complete when 
there was no aldehyde peak present in the NMR spectrum. 
The solvent was removed in vacuo and the crude imine dis-
solved in CH2Cl2/MeOH (1:1, 10 mL). The solution was 
cooled to 0° C. and sodium borohydride (60 mg, 1.5S mmol) 
was added in 15 mg portions over 30 minutes. TLC (10% 
EtAc/hexane) showed the reaction to be complete after stir-
ring overnight. The solvent was removed in vacuo and the 
crude solid dissolved in CH2Cl2 (50 mL) and washed with 
sodium carbonate (10% aq, 3x40 mL ). The CH2Cl2 layer was 
dried over sodium sulfate, filtered, the solvent removed in 
vacuo and the solid residue purified by flash colunm chroma-
tography (1:10:S9 NH40H:MeOH:CHCl3) to give the prod-
uct 16 as a white solid (0.15 g, 63%), Rf=0.5 (1:10:S9 
NH40H:MeOH:CHCl3). 1 H NMR (CDCl3) d 6.S5 (s, lH, 
aryl), 6.SO (m, 2H, aryl), 5.34 (t, 4H, olefinic), 3.97 (q, 4H, 
OCH2), 3.69 (s, 2H, benzylic), 2.67 (t, 2H, CH2NH2), 2.60 (t, 
2H, CH2NH2), 2.01 (m, SH, CH2C=C), r:so (m, 4H, c 
H2CH;l}), 1.54-1.lS (m, 56H, 2SxCH2), O.SS (t, 6H, CH3); 
tic NMR (CDCl3) d 149.31, 14S.20, 133.55, 130.11, 130.00, 
120.59, 114.14, 114.07, 69.70, 69.50, 54.24, 49.S3, 42.60, 
34.20, 32.2S, 30.46, 30.16, 29.92, 29.Sl, 29.71, 29.67, 27.73, 
27.60, 27.22, 26.44, 23.0S, 14.53; HRMS (FAB): theory for 
C51 H95N20 2 (M+l), 767.7394; found (M+l), 767.7377. 
Anal. (C51 H94N20 2.0.3H20): C, H, N. 
2-{ 2-[2-(3,4-Bis-octadec-9-enyloxy-benzylamino )-ethoxy ]-
ethoxy }-ethylamine (17): 
To a vigorously stirred solution of diaminodioxaoctane 
(0.23 g, 1.56 mmol, 5 equiv) in CH2Cl2/MeOH (3:1, 5 mL) 
20 minutes at 0° C. The suspension was hydrogenated at 50 45 
psi for 24 hours. Air was bubbled through the solution and the 
Raney nickel was removed by filtering through a sintered 
glass funnel keeping the Raney nickel residue moist at all 
times. The ethanol and NH40H were removed in vacuo and 
the oily residue dissolved in CH2Cl2 and washed with sodium 50 
carbonate (10%, aq, 3x50 mL). The organic layer was dried 
over anhydrous sodium sulphate, filtered and the solvent 
removed in vacuo. The oil was purified by flash column 
chromatography (1:10:S9 NH40H:MeOH:CHCl3) to give 
the product 14 as a clear oil (O.S5 g, 64%), Rf=0.5 (1:10:S9 55 
NH40H:MeOH:CHCl3). 1 H NMR (CDCl3) d 4.65 (s, lH, 
NHCO), 3.15 (m, !OH, 5xCH2), 2.70 (t, 2H, CH2NH2), 1.5S-
1.39 (m, 39H, 6xCH2, 9xCH3); HRMS (FAB): theory for 
C27H55N40 6 (M+l), 531.4122; found (M+l), 531.4111; 
Anal. Calcd (C27H54N40 60.1H20): C, H, N. 60 was added a solution of the aldehyde Sa (0.20 g, 0.33 mmol) 
in CH2Cl2/MeOH (3:1, 5 mL), dropwise over 1 hour. The 
resulting mixture was stirred at rt under an atmosphere of 
nitrogen overnight. NMR showed the reaction to be complete 
[ 4-(3 ,4-Bis-octadec-9-eny loxy-benzy !amino )-butyl ]-car-
bamic acid tert-butyl ester (15): 
To a vigorously stirred solution of the amine 9 (0.071 g, 
0.3S mmol, 1.2 equiv) in CH2CliMeOH (3:1, 5 mL) was 
added a solution of the aldehyde Sa (0.20 g, 0.33 mmol) in 65 
CH2Cl2/MeOH (3:1, 5 mL), dropwise over 20 minutes. The 
resulting mixture was stirred at it under an atmosphere of 
when there was no aldehyde peak present in the NMR spec-
trum. The solvent was removed in vacuo and the crude imine 
dissolved in CH2CVMeOH (1:1, 10 mL). The solution was 
cooled to 0° C. and NaBH4 (60 mg, 1.5S mmol) was added in 
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15 mg portions over 30 minutes. TLC (10% EtAc/hexane) 
showed the reaction to be complete after stirring overnight. 
The solvent was removed in vacuo and the crude oil dissolved 
in CH2Cl2 (50 mL) and washed with sodium carbonate (10% 
aq, 3x40 mL). The CH2 Cl2 layer was dried over anhydrous 5 
Na2S04 , filtered, the solvent removed in vacuo and the oily 
residue purified by flash column chromatography (1:10:S9 
NH4 0H:MeOH:CHCl3 ) to give the product 17 as a clear oil 
(0.16S g, 70%), Rf=0.45 (1:10:S9 NH4 0H:MeOH:CHCl3 ). 
1HNMR(CDCl3 ) d6.S7 (s, lH, aryl), 6.Sl (m, 2H, aryl), 5.34 10 
(t, 4H, olefinic), 3.97 (q, 4H, OCH2 ), 3.72 (s, 2H, benzylic), 
3.61 (m, 6H, OCH2), 3.61 (t, 2H, OCH2), 2.S6 (t, 2H, C 
H2NH2), 2.Sl (t, 2H, CH2NH2 ), 2.01 (m, SH, CH2 C=C), 
I.SO (m, 4H, CH2CH2 0)-;-1.54-1.17 (m, 44H, 22xCH2 ), O.S9 
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EtAc/hexane) showed the reaction to be complete after stir-
ring overnight. The solvent was removed in vacuo and the 
crude oil dissolved in CH2Cl2 (50 mL) and washed with 
sodium carbonate (10% aq, 3x40 mL ). The CH2Cl2 layer was 
dried over sodium sulphate, filtered, the solvent removed in 
vacuo and the oily residue purified by flash column chroma-
tography (3% MeOH/CHCl3 ) to give the product 19 as a clear 
oil (0.319 g, SS%), Rf=0.25 (3% MeOH/CHCl3 ). 1H NMR 
(CDCl3 ) d 6.S5 (s, lH, aryl), 6.SO (m, 2H, aryl), 5.34 (t, 4H, 
olefinic), 4.60 (brs, lH, NHCO), 3.97 (q, 4H, OCH2 ), 3.70 (s, 
2H, benzylic), 3.14 (m, lOH, 5xCH2 ) 2.64 (t, 2H, CH2NH), 
2.01 (m, SH, CH2C=C), 1.SO (m, 4H, CH2CH2 0), 1.39-1.14 
(m, S3H, 2SxCH2 , 9xCH3 ), O.S9 (t, 6H, CH3 ); 13C NMR 
(CDCl3 ) d 156.12, 155.69, 149.33, 14S.25, 133.2S, 130.10, 
129.99, 120.61, 114.14, 114.07, 79.40, 69.69, 69.50, 54.15, 
49.47, 47.24, 46.9S, 40.57, 32.27, 30.14, 29.90, 29.SO, 29.69, 
29.66, 2S.S5, 2S.79, 27.77, 27.5S, 26.44, 23.07, 14.53; 
HRMS (FAB): theory for C70H129N4 0 8 (M+l), 1153.9S10; 
found (M+l), 1153.9S40;Anal. Calcd (C70H128N4 0 8): C, H, 
(t, 6H, CH3 ); 1TC NMR (CDCl3 ) d 149.31, 14S.25, 133.11, 15 
130.09, 129.99, 120.73, 114.26, 114.07, 73.57, 70.S5, 70.57, 
70.52, 69.69, 69.51, 54.02, 4S.93, 42.01, 32.2S, 30.15, 29.91, 
29.SO, 29.70, 29.67, 27.59, 26.45, 26.42, 23.07, 14.53; 
HRMS (FAB): theory for C49H91N2 0 4 (M+l), 771.6979; 
found (M+l), 771.6995; Anal. (C49H90N2 0 4 ): C, H, N. 20 N. 
( 4-{[ 4-(3,4-Bis-octadec-9-enyloxy-benzylamino )-butyl]-
tert-butoxycarbonyl-amino }-butyl)-carbamic acid tert-butyl 
ester (IS): 
To a vigorously stirred solution of the amine 12 (0.135 g, 
0.3S mmol, 1.2 equiv) in CH2CliMeOH (3:1, 5 mL) was 25 
added a solution of the aldehyde Sa (0.20 g, 0.33 mmol) in 
CH2 Cl2/MeOH (3:1, 5 mL), dropwise over 20 minutes. The 
resulting mixture was stirred at RT under an atmosphere of 
nitrogen overnight. NMR showed the reaction to be complete 
when there was no aldehyde peak present in the NMR spec- 30 
trum. The solvent was removed in vacuo and the crude imine 
dissolved in CH2 Cl2/MeOH (1:1, 10 mL). The solution was 
cooled to 0° C. and sodium borohydride (60 mg, 1.5S mmol) 
was added in 15 mg portions over 30 minutes. TLC (10% 
EtAc/hexane) showed the reaction to be complete after stir- 35 
ring overnight. The solvent was removed in vacuo and the 
crude oil dissolved in CH2Cl2 (50 mL) and washed with 
sodium carbonate (10% aq, 3x40 mL ). The CH2Cl2 layer was 
dried over sodium sulphate, filtered, the solvent removed in 
vacuo and the oily residue purified by flash column chroma- 40 
tography (3% MeOH/CHCl3 ) to give the product 1 Sas a clear 
oil (0.24 g, 7S%), Rf=0.3 (3% MeOH/CHCl3 ). 1H NMR 
(CDCl3 ) d 6.S5 (s, lH, aryl), 6.SO (m, 2H, aryl), 5.34 (t, 4H, 
olefinic), 4.60 (brs, lH, NHCO), 3.97 (q, 4H, OCH2 ), 3.69 (s, 
2H, benzylic), 3.13 (m, 6H, CH2 ) 2.63 (t, 2H, CH2NH), 2.01 45 
(m, SH, CH2 C=C), 1.SO (m, 4H, CH2CH2 0), 1-:67-1.15 (m, 
70H, 26xCH2 , 6xCH3 ), O.S9 (t, 6H, CH3 ); 13C NMR (CDCl3 ) 
d 156.17, 155.71, 149.33, 14S.25, 133.31, 130.11, 130.00, 
120.62, 114.15, 114.0S, 79.45, 69.70, 69.51, 54.13, 49.42, 
47.34, 46.S9, 40.5S, 32.2S, 30.14, 29.91, 29.SO, 29.70, 29.67, 50 
2S.S5, 2S.79, 27.79, 27.70, 27.59, 26.42, 23.07, 14.53; 
HRMS (FAB): theory for C61 H112N3 0 6 (M+l), 9S2.S551; 
found (M+l), 9S2.S510; Anal. (C61 HrnN30 6 ): C, H, N. 
( 4-{[ 4-(3,4-Bis-octadec-9-enyloxy-benzylamino )-butyl]-
tert-butoxycarbony I-amino }-buty I)-( 4-tert-butoxycarbony- 55 
lamino-butyl)-carbamic acid tert-butyl ester (19): 
To a vigorously stirred solution of the amine 14 (0.20 g, 
0.3S mmol, 1.2 equiv) in CH2CliMeOH (3:1, 5 mL) was 
added a solution of the aldehyde Sa (0.20 g, 0.33 mmol) in 
CH2 Cl2/MeOH (3:1, 5 mL), dropwise over 20 minutes. The 60 
resulting mixture was stirred at RT under an atmosphere of 
nitrogen overnight. NMR showed the reaction to be complete 
when there was no aldehyde peak present in the spectrum. 
The solvent was removed in vacuo and the crude imine dis-
solved in CH2 Cl2/MeOH (1:1, 10 mL). The solution was 65 
cooled to 0° C. and sodium borohydride (60 mg, 1.5S mmol) 
was added in 15 mg portions over 30 minutes. TLC (10% 
( 4-{ [ 4-(3,4-Bis-octadec-9-enyloxy-benzoylamino )-butyl]-
tert-butoxycarbonyl-amino }-butyl)-carbamic acid tert-butyl 
ester (20): 
A solution of 3,4-Bis-octadec-9-enyloxy-benzoic acid Sc 
(0.2 g, 0.31 mmol) in 2:1 dichloromethane/benzene (15 mL) 
was stirredat0° C. for lOmin.AnhydrousDMF (2 drops) and 
oxalyl chloride (0.3 mL) were added in sequence and the 
mixture was stirred for 1 hat 0° C. The solution was concen-
trated in vacuo to give the crude acid chloride, Sd. Crude Sd 
was dissolved in CH2Cl2 (10 mL) and added dropwise to a 
solution of the amine 12 (0.132 g, 0.37 mmol, 1.2 equiv.) 
dissolved in CH2 Cl2 (10 mL) and lMNaOH (10 mL) thathad 
been cooled to 0° C. for 15 minutes. The reaction was stirred 
overnight under N 2 at room temperature. The water layer was 
separated off. The CH2Cl2 layer was washed with Na2C03 
(10% aq. 3x20 mL), dried over Na2 S04 , filtered, removed in 
vacuo and the oily residue purified by flash column chroma-
tography (30% EtAc/hexane) to give the product 20 as a clear 
oil (0.261 g, S6%), Rf=0.25 (30% EtAc/hexane); 1H NMR 
(500 MHz, CDCl3 ) d 7.50-7.20 (m, 2H, phenyl), 6.90 (br s, 
0.5H, NHCO), 6.Sl (d, lH,phenyl), 6.41(brs,0.5H, NHCO), 
5.35 (t, 4H, olefinic), 4.6S (m, lH, NHCO), 3.99 (2t, 4H, 
2xOCH2 ), 3.44 (m, 2H, CH2 ), 3.11(m,6H, 3xCH2), 2.00 (m, 
SH, CH2C=C), 1.79 (m, 4H, CH2CH2 0), 1.53-1.17 (m, 70H, 
26xCH2 , 6xCH3 ), O.SS (t, 6H;-CH3 ); 13C NMR (CDCl3 ) d 
167.32, 156.lS, 151.S4, 14S.9S, 130.11, 130.09, 127.32, 
113.02, 112.39, 79.62, 79.32, 69.52, 69.36, 47.09, 40.49, 
39.92, 32.26, 30.13, 29.S9, 29.76, 29.6S, 29.65, 29.62, 29.59, 
29.50, 2S.S4, 2S.77, 27.79, 27.5S, 26.3S, 26.36, 23.06, 14.51; 
HRMS (FAB): theoryforC61H109N3 0 7 (M+Na), 101S.S15S; 
found (M+Na), 101S.S123; Anal. (C61H109N3 0 7 ): C, H, N. 
( 4-{ [ 4-(3,4-Bis-octadec-9-enyloxy-benzoylamino )-butyl]-
tert-butoxycarbonyl-amino }-buty !)-( 4-tert-butoxycarbony-
lamino-buty l )-carbamic acid tert-butyl ester (21): 
A solution of 3,4-Bis-octadec-9-enyloxy-benzoic acid Sc 
(0.2 g, 0.31 mmol) in 2:1 dichloromethane/benzene (15 mL) 
was stirredat0° C. for lOmin.AnhydrousDMF (2 drops) and 
oxalyl chloride (0.3 mL) were added in sequence and the 
mixture was stirred for 1 hat 0° C. The solution was concen-
trated in vacuo to give the crude acid chloride Sd. The acid 
chloride Sd was dissolved in CH2 Cl2 (10 mL) and added 
dropwise to a solution of the amine 14 (0.195 g, 0.37 mmol, 
1.2 equiv.) dissolved in CH2 Cl2 (10 mL) and IM NaOH (10 
mL) that had been cooled to 0° C. for 15 minutes. The reaction 
was stirred overnight under N2 at room temperature. The 
water layer was separated off. The CH2Cl2 layer was washed 
with Na2C03 (10% aq. 3x20 mL), dried over Na2 S04 , fil-
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tered, removed in vacuo and the oily residue purified by flash 
colunm chromatography (30% EtAc/hexane) to give the 
product 21 as a clear oil (0.295 g, S3% ), Rf=0.20 (30% EtAc/ 
hexane); 1H NMR (500 MHz, CDC13 ) d 7.42-7.20 (m, 2H, 
phenyl), 6.S2 (br s, 0.5H, NHCO), 6.SO (d, lH, phenyl), 6.39 5 
(br s, 0.5H, NHCO), 5.35 (t, 4H, olefinic), 4.65 (m, lH, 
NHCO), 3.99 (2xt, 4H, 2xOCH2), 3.42 (m, 2H, CH2 ), 3.13 
(m, !OH, 5xCH2 ), 2.00 (m, SH, CH2 C=C), 1.79 (m, 4H, C 
H2 CH20), 1.53-1.17 (m, S3H, 2SxCH2 , 9xCH3 ), O.SS (t, 6H, 
CH3 ); 13C NMR (CDC13 ) d 167.35, 156.16, 155.73, 151.SS, 10 
14S.99, 130.13, 130.11, 127.37, 113.05, 112.41, 79.54, 
69.54, 69.3S, 47.03, 40.5S, 39.97, 32.27, 30.14, 29.90, 29.77, 
29.69, 29.66, 29.63, 29.60, 29.51, 2S.S5, 2S.79, 27.7S, 27.59, 
26.40, 26.37, 23.07, 14.53; HRMS (FAB): theory for 
C70H126N4 0 9 (M+Na), 11S9.9407; found (M+Na), 15 
11S9.9365; Anal. (C70H126N4 0 8 ): C, H, N. 
N1 -(3,4-Bis-octadec-9-enyloxy-benzyl)-butane- l ,4-di-
amine, dihydrochloride salt (22): 
A concentrated solution of the amine 15 (0.15S g, 0.19 
mmol) in ethyl acetate was added cooled to 0° C. A total of 4 20 
mL of a freshly prepared saturated solution of HCl in ethyl 
acetate was added dropwise and the solution stirred for 1 hat 
room temperature during which time a white precipitate 
formed. The ethyl acetate was removed in vacuo and the 
residue co-evaporated with ethyl acetate and chloroform to 25 
give the product 22 as an off white powder (0.15 g, 9S%); 1H 
NMR (500 MHz, CDC13 ) d 9.50 (br s, 2H, R2WH2 ), S.22 (br 
s, 3H, RWH3 ), 7.24 (s, lH, aryl), 7.05 (d, lH, aryl), 6.S2 (d, 
lH, aryl), 5.34 (m, 4H, olefinic), 4.02 (q, 4H, OCH2 ), 3.93 (t, 
2H, benzylic), 3.07 (m, 2H, CH2 )2.Sl (m, 2H, CH2 ), 2.01 (m, 30 
SH, CH2 C=C), 1.95 (m, 2H, CH2 ), 1.S5 (m, 2H, CH2 ), 1.7S 
(m, 4H, CH2 CH20), 1.45 (m, 4H, 2xCH2 ), 1.3S-1.20 (m, 
40H, 20xCH2 ), O.S9 (t, 6H, CH3 ); 13C NMR (300 MHz, 
CDC13 ) d 150.00, 149.37, 130.12, 130.09, 129.95, 122.5S, 
115.Sl, 113.49, 69.63, 69.3S, 51.44, 51.06, 45.SO, 39.63, 35 
32.29, 30.24, 30.21, 30.16, 30.00, 29.93, 29.71, 27.61, 26.63, 
26.49, 24.S3, 23.75, 23.0S, 14.54; HRMS (FAB): theory for 
C47H37N2 0 2 (M+l), 711.676S; found (M+l), 711.6S27; 
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and the residue co-evaporated with ethyl acetate and chloro-
form to give the product 24 as an off white powder (0.15 g, 
9S%); 1H NMR (CDC13 ) d 7.27 (s, lH, aryl), 7.00 (d, lH, 
aryl), 6.S2 (d, lH, aryl), 5.33 (m, 4H, olefinic), 4.14 (m, 2H, 
benzylic), 4.01 (t, 2H, OCH2), 3.95 (t, 2H, OCH2), 3.S7 (t, 
2H, CH2 ), 3.7S (t, 2H, CH2 ), 3.70 (t, 4H, CH2 ), 3.25 (t, 2H, 
CH2 ) 2.93 (m, 2H, CH2 ), 2.02 (m, SH, CH2C=C), 1.S9 (m, 
4H, CH2CH2 0), 1.53-1.lS (m, 44H, 22xCH2 ), O.S9 (t, 6H, 
CH3);-1:3C NMR (300 MHz, CDC13 ) d 149.91, 149.62, 
130.12, 130.00, 123.2S, 122.61, 115.46, 113.63, 70.22, 
70.09, 69.64, 69.40, 66.50, 65.9S, 51.06, 45.0S, 40.11, 32.2S, 
30.15, 29.92, 29.70, 27.60, 26.54, 26.43, 23.07, 14.54; 
HRMS (FAB): theory for C49H91N2 0 4 (M+l), 771.6973; 
found(M+l), 771.6967;Anal. (C49H92Cl2 N20 4 .0.4H2 0): C, 
H,N. 
N-( 4-Amino-butyl )-N'-(3 ,4-bis-octadec-9-eny loxy-benzyl )-
butane-1,4-diamine, tri hydrochloride salt (25): 
A concentrated solution of the amine IS (0.17 g, 0.17 
mmol) in ethyl acetate was added cooled to 0° C. A total of 4 
mL of a freshly prepared saturated solution of HCl in ethyl 
acetate was added dropwise and the solution stirred for 1 hat 
room temperature during which time a white precipitate 
formed. The ethyl acetate was removed in vacuo and the 
residue co-evaporated with ethyl acetate and chloroform to 
give the product 25 as a white powder (0.151 g, 9S%); 1H 
NMR (CDC13 /CH3 0D 9:1) d 7.13 (s, lH, aryl), 7.02 (d, lH, 
aryl), 6.S5 (d, lH, aryl), 5.33 (m, 4H, olefinic), 4.05 (m, 2H, 
benzylic), 3.97 (t, 2H, OCH2 ), 3.04 (m, 6H, 3xCH2 ) 2.93 (m, 
2H, CH2 ), 2.02 (m, SH, CH2 C=C), 1.90 (m, SH, 4xCH2 ), 
1.Sl (m, 4H, CH2 CH2 0), 1.47 (m, 4H, 2xCH2 ), 1.40-1.17 (m, 
40H, 20xCH2)-;-0.S9 (t, 6H, CH3 ); 13C NMR (300 MHz, D2 0) 
ll 14S.94, 14S.33, 129.26, 129.19, 123.64, 122.52, 113.10, 
6S.50, 6S.39, 49.96, 45.9S, 45.43, 39.S6, 31.2S, 29.lS, 29.11, 
2S.93, 2S.S6, 2S.70, 2S.62, 26.64, 26.59, 25.6S, 25.62, 24.00, 
22.54, 22.46, 22.11, 13.S9; HRMS (FAB): theory for 
C51 H96N3 0 2 (M+l), 7S2.7497; found (M+l), 7S2.7495; 
Anal. (C51 H95Cl3 N3 0 2 .0.6H2 0): C, H, N. 
N-[ 4-( 4-Amino-butylamino )-butyl]-N'-(3,4-bis-octadec-9-
enyloxy-benzyl)-butane-l,4-diamine, tetrahydrochloride salt Anal. (C47H88Cl2N2 0 4 .l.2H2 0): C, H, N. 
N1 -(3,4-Bis-octadec-9-enyloxy-benzyl)-octane- l ,S-di-
amine, dihydrochloride salt (23): 
40 (26): 
A concentrated solution of the amine 16 (0.097 g, 0.13 
mmol) in ethyl acetate was added cooled to 0° C. A total of 4 
mL of a freshly prepared saturated solution of HCl in ethyl 
acetate was added dropwise and the solution stirred for 1 hat 45 
room temperature during which time a white precipitate 
formed. The ethyl acetate was removed in vacuo and the 
residue co-evaporated with ethyl acetate and chloroform to 
give the product 23 as an off white powder (0.104 g, 9S% ); 1 H 
NMR (CDC13 ) d 7.24 (s, lH, aryl), 7.05 (d, lH, aryl), 6.S5 (d, 50 
lH, aryl), 5.35 (m, 4H, olefinic), 4.07 (q, 4H, OCH2 ), 3.95 (t, 
2H, benzylic), 3.07 (m, 2H, CH2 )2.79 (m, 2H, CH2 ), 2.05 (m, 
SH, CH2 C=C), 1.S2 (m, SH, CH2CH2 0, 2xCH2 ), 1.5S-1.21 
(m, 52H, 26xCH2 ), O.S9 (t, 6H,L:H3 ); 13C NMR (300 MHz, 
CDC13 ) d 149.36, 14S.7S, 130.S5, 130.33, 129.74, 122.23, 55 
115.56, 113.45, 69.56, 69.32, 51.56, 51.15, 45.96, 39.S6, 
32.53, 30.44, 30.44, 30.23, 30.12, 30.00, 29.71, 27.61, 27.51, 
27.10, 26.S3, 26.69, 24.S2, 23.77, 23.0S, 14.54; HRMS 
(FAB): theory for C51H95N20 2 (M+l), 767.7394; found 
(M+l), 767.7419;Anal. (C51H96Cl2N2 0 2 .0.3H20): C, H, N. 60 
2-{ 2-[2-(3,4-Bis-octadec-9-enyloxy-benzylamino )-ethoxy ]-
ethoxy }-ethylamine, dihydrochloride salt (24): 
A concentrated solution of the amine 17 (0.14 g, O.lS 
mmol) in ethyl acetate was added cooled to 0° C. A total of 4 
mL of a freshly prepared saturated solution of HCl in ethyl 65 
acetate was added dropwise and the solution stirred for 1 hat 
room temperature. The ethyl acetate was removed in vacuo 
A concentrated solution of the amine 19 (0.253 g, 0.22 
mmol) in ethyl acetate was added cooled to 0° C. A total of 5 
mL of a freshly prepared saturated solution of HCl in ethyl 
acetate was added dropwise and the solution stirred for 1 hat 
room temperature during which time a white precipitate 
formed. The ethyl acetate was removed in vacuo and the 
residue co-evaporated with ethyl acetate and chloroform to 
give the product 26 as a white powder (0.215 g, 9S%); 1H 
NMR (CD3 0D) ll 7.13 (s, lH, aryl), 7.04 (d, lH, aryl), 6.9S 
(d, lH, aryl), 5.33 (t, 4H, olefinic), 4.12 (m, 2H, benzylic), 
4.03 (t, 2H, OCH2 ), 3.99 (t, 2H, OCH2 ), 3.0S (m, !OH, 
5xCH2 ), 2.9S (t, 2H, CH2 ), 2.02 (m, SH, CH2C=C), 1.S9 (m, 
16H, SxCH2 ), 1.47 (m, 4H, 2xCH2), 1.42-1.19 (m, 40H, 
20xCH2 ), O.S9 (t, 6H, CH3 ); 13C NMR (300 MHz, D20) ll 
149.74, 14S.90, 129.62, 129.46, 123.92, 123.71, 69.36, 
6S.SS, 51.12, 46.6S, 3S.99, 32.14, 29.97, 29.Sl, 29.60, 27.36, 
26.53, 24.69, 24.22, 23.14, 23.06, 22.S4, 14.05; HRMS 
(FAB): theory for C55H105N4 0 2 (M+l), S53.S23S; found 
(M+l), S53.S264;Anal. (C55H109Cl4 N4 0 2 .0.6H20): C, H, N. 
N-[ 4-( 4-Amino-butylamino )-butyl]-3,4-bis-octadec-9-eny-
loxy-benzamide, dihydrochloride salt (27): 
A concentrated solution the amide 20 (0.22 g, 0.22 mmol) 
in ethyl acetate was added cooled to 0° C. A total of 5 mL of 
a freshly prepared saturated solution ofHCl in ethyl acetate 
was added dropwise and the solution stirred for 1 h at room 
temperature during which time a white precipitate formed. 
The ethyl acetate was removed in vacuo and the residue 
US 7,910,363 Bl 
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R1 and R2 may be the same or may be different and com-
prise a long hydrocarbon chain which is between six and 
eighteen carbons long and either contains or does not contain 
units of unsaturation. For example, the chain could be derived 
from the C18 oleic acid and attached via an ester linkage or via 
an ether linkage and an oleyl group. The chains can range 
from lauryl, stearic, myristic and oleic acids. 
R3 is a polycation comprising a polyamine side chain. 
co-evaporated with ethyl acetate and chloroform to give the 
product 27 as a white powder (0.19 g, 98%); 1H NMR 
(CDC13 ) d 8.95 (br s, 2H, R2WH2 ), 8.20 (br s, 3H, RWH3 ), 
7.45 (m, 2H, aryl), 6.78 (m, lH, aryl), 5.33 (m, 4H, olefinic), 
3.95 (m, 4H, OCH2), 3.38 (m, 2H, CH2), 3.11 (m, 2H, CH2), 5 
3.01 (m, 4H, 2xCH2), 2.08-1.89 (m, 14H, 7xCH2 ), 1.71 (m, 
6H, 3xCH2 ), 1.47-1.18 (m, 44H, 20xCH2 ), 0.89 (t, 6H, CH3 ); 
HRMS (FAB): theory for C51H94N3 0 3 (M+l), 796.7290; 
found (M+ 1 ), 796.7249; Anal. (C51 H95Cl2N3 0 3 . l .6H2 0): C, 
H,N. 
These aliphatic polyamine side chains can range from mono 
10 amines to octaamines with carbon spacer groups ranging 
from two to six in between the nitrogen centers. These can 
also be branched systems as well. For example: 
N-{ 4-[ 4-( 4-Amino-butylamino )-butylamino ]-butyl }-3,4-
bis-octadec-9-enyloxy-benzamide, trihydrochloride salt 
(28): 
A concentrated solution of the amide 21 (0.22 g, 0.19 
mmol) in ethyl acetate was added cooled to 0° C. A total of 5 15 
mL of a freshly prepared saturated solution of HCl in ethyl 
acetate was added dropwise and the solution stirred for 1 hat 
room temperature during which time a white precipitate 
formed. The ethyl acetate was removed in vacuo and the 
residue co-evaporated with ethyl acetate and chloroform to 20 
give the product 28 as a white powder (0.18 g, 98% ); 1 H NMR 
(CDC13/CH30D 9:1) d 7.42 (m, 2H, aryl), 6.78 (m, lH, aryl), 
5.33 (m, 4H, olefinic), 4.03 (m, 4H, OCH2 ), 3.41 (m, 2H, 
CH2 ), 3.01 (m, !OH, 5xCH2), 2.08-1.66 (m, 24H, 12xCH2), 
1.71 (m, 6H, 3xCH2), 1.56-1.13 (m, 44H, 20xCH2), 0.89 (t, 25 
6H, CH3 ); HRMS (FAB): theory for C55H105N4 0 3 (M+l), 
867.8025; found (M+l), 867.8022; Anal. Calcd for 
(C55H105Cl3N4 0 3 .l.5H2 0): C, H, N. 
Advantages of the present invention include the surprising 
discovery that compound (#26) is much more efficient in 30 
delivering DNA into a target cell than the commercial Lipo-
fectamine™ transfection agent.39 This efficiency, coupled 
with the straightforward synthesis we developed for this 
material makes this product commercially viable to pursue. 
Uses of compound #26 and other compounds herein dis- 35 
closed include use as smart anticancer agents which recog-
nize and selectively deliver "cargoes" to specific cell types. 
The cargoes could be either 'corrective' DNA which repairs 
or replaces the cancerous genetic lesion and allows forthe cell 
to heal itself. Alternatively, one could deliver toxic com- 40 
pounds such as the plant toxin saporin, which targets cell 
protein synthesis ability. Blocking protein synthesis is a toxic 
event for the cell. Therefore, one could envision delivering 
toxic compounds selectively to cancer cells to kill them, even 
in the presence of normal healthy cells. Coadministration of 45 
the agent saporin with a lipopolyamine was shown to promote 
entry of the agent into cells by the cell's own polyamine 
transporter system. These results were published in FEBS J., 
274 (2007) 4825-4836, a paper which is noted above and 
which has been incorporated herein by reference in its 50 
entirety. 
A deficiency in previously known compounds is their 
lower efficiency of transfection and their inability to target 
specific cell types via the polyamine transport system. 
EXAMPLES 
I. 
I R3 R,OXY' 
R10 _# 
55 
60 
65 
-NHCH3 
-NH-(CH2)aNH(CH2)bNH2 
-NH-(CH2laNH(CH2)bNH(CH2)cNH2 
-NH-(CH2laNH(CH2)bNH(CH2)cNH(CH2)dNH2 
-NH-(CH2laNH(CH2)bNH(CH2)cNH(CH2)dNH 
(CH2)eNH2 
-NH-(CH2)aNH(CH2)bNH(CH2)cNH(CH2)dNH 
(CH2)eNH(CH2)_,NH2 
-NH-(CH2)aNH(CH2)bNH(CH2)cNH(CH2)dNH 
(CH2)eNH(CH2)_,NH(CH2),,NH2 
where a-g range from two to six 
Note: other polycationic moieties may be used in place of the 
polyamine. More biofriendly cations like polyhistine, pol-
yarginine, polylysine or polyornithine peptides could be 
used. These could be in the all L, all D or mixed L,D forms. In 
addition, the hydrochloride salts as well as other pharmaceu-
tically acceptable salt forms of compound 1 could be used. 
II. 
2 
R1 and R2 are the same or different and are comprised of a 
long hydrocarbon chain which is between six and eighteen 
carbons long and either contains or does not contain units of 
unsaturation. For example, the chain could be derived from 
the C18 oleic acid and attached via an ester linkage or via an 
ether linkage and an oleyl group. The chains can range from 
lauryl, stearic, myristic and oleic acids. 
R3 is a polycations comprised of a polyamine side chain. 
These aliphatic polyamine side chains can range from mono 
amines to octaamines with carbon spacer groups ranging 
from two to six in between the nitrogen centers. These can 
also be branched systems as well. 
-NHCH3 
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-NH-(CH2)aNH(CH2)bNH2 
-NH-(CH2laNH(CH2)bNH(CH2)cNH2 
-NH-(CH2)aNH(CH2)bNH(CH2)cNH(CH2)dNH 
(CH2)eNH2 
-NH-(CH2)aNH(CH2)bNH(CH2)cNH(CH2)dNH 
(CH2)eNH(CH2)_iNH2 
-NH-(CH2)aNH(CH2)bNH(CH2)cNH(CH2)dNH 
(CH2)eNH(CH2)_iNH(CH2),,NH2 
where a-g range from two to six 
10 
15 
22 
3. Feigner, P. L.; Rhodes, G. Gene Therapeutics. Nature 1991, 
349, 351-352. 
4. Smythe-Templeton, N.; Lasic, D. D., Eds. Gene Therapy. 
Therapeutic Mechanisms and Strategies; Marcel Dekker 
Inc.: New York, 2000. 
5. a) Cogoni, C.; Macina, G. Post-transcriptional gene silenc-
ing across kingdoms. Genes Dev 2000, 10, 638-643; b) 
Guru T. A silence that speaks volumes. Nature 2000. 404, 
804-808; c)Hammond, S. M,; Caudy, A.A.; Hannon, G. J. 
Post-transcriptional Gene Silencing by Double-stranded 
RNA. Nature Rev Gen. 2001, 2, 110-119; d) Gitlin. L.; 
Karelsky, S.; Andino, R. Short interfering RNA confers 
intracellular antiviral immunity in human cells Nature 
2002, 418, 430-434. 
6. Wang, D.; Zheng, F.; Holmberg, S.; Kohlhaw, G. B. Yeast 
Transcriptional Regulator Leu3p ?self-masking, specific-
ity of masking, and evidence for regulation by the intrac-
ellular level ofLeu3p. J. Biol. Chem., 1999, 274, 19017-
19024. 
7. Chisaka, O.; Capecchi, M. R. Regionally restricted devel-
opmental defects resulting from targeted disruption of the 
mouse homeobox gene hox-1.5. Nature 1991, 350, 473-
479. 
Note: other polycationic moieties may be used in place of the 20 
polyamine. More biofriendly cations like poly-histine, pol-
yarginine, polylysine or polyomithine peptides could be 
used. These could be in the all L, all D or mixed L,D forms. In 
addition, the hydrochloride salts as well as other pharmaceu-
tically acceptable salt forms of 2 could be used as well. 25 8. Smith, A. E. Viral Vectors in Gene Therapy. Annu. Rev. 
III. Pharmaceutical compositions of either 1 and/or 2 along 
with a neutral lipid (e.g., DOPE) and a therapeutic agent such 
Microbial. 1995, 49, 807-838. 
9. Kay, M.A.; Glorioso, J. C.; Naldini, L. Viral vectors for 
gene therapy: the art of turning infectious agents into 
vehicles of therapeutics. Nat. Med. 2001, 7, 33-40. 
10. Feigner, P. L.; Gadek, T. R.; Holm, M.; Roman, R.; Chan, 
H. W.; Wenz, M.; Northrop, J. P.; Ringold; G. M.; 
Danielsen, M. Lipofectin: A highly efficient, lipid-medi-
ated DNA-transfection procedure. Proc. Natl. Acad. Sci. 
USA. 1987, 84, 7413-7417. 
as a DNA plasmid, siRNA (gene silencing agent), or toxic 
compound. The DNA plasmid could be a corrective gene to 
repair or replace a damaged gene within the cell. The siRNA 30 
could be a RNA molecule designed to silence a bad gene to 
provide a positive therapeutic outcome. The toxic compound 
could be a toxic drug that kills the cell like methotrexate, 
doxorubicin, cis platin, taxol, or other toxins like saporin or 
ricin which target specific critical cell functions. 35 11. Behr, J. P.; Demeneix, B.; Loeffler, J-P.; Perez-Mutul, J. 
Summary. The invention will allow forthe selective deliv-
ery of therapeutic agents to cancer cells via the polyamine 
transport system. The technology is predicated upon the fact 
that certain cancer cells readily import polyamines from their 
environment. This property provides an opportunity to target 40 
these cells via their selective uptake of these cationic materi-
als. The patented materials can also delivery other therapeutic 
agents to cells such as DNA plasmids, RNA for gene silenc-
ing therapies, and proteins which repair or destroy cells. The 
technology also allows for enhanced transfection of cells by 45 
utilizing this special uptake pathway to deliver new genes, 
nucleic acids and proteins into cells. 
Accordingly, in the drawings and specification there have 
been disclosed typical preferred embodiments of the inven-
tion and although specific terms may have been employed, the 50 
terms are used in a descriptive sense only and not for purposes 
of limitation. The invention has been described in consider-
able detail with specific reference to these illustrated embodi-
ments. It will be apparent, however, that various modifica-
tions and changes can be made within the spirit and scope of 55 
the invention as described in the foregoing specification and 
as defined in the appended claims. 
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10. The vector of claim 8, wherein said agent comprises 
DNA. 
11. The vector of claim 8, wherein said agent comprises a 
trans gene. 
12. Thevectorof claim 8, wherein said agent is toxic forthe 
cell. 
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13. A method of delivering an agent into a cell, the method 
comprising associating the agent with a polyamine cationic 
lipid selected from compounds (25), (26), (27), (28), their 
60 pharmaceutically acceptable salts and combinations thereof 
and contacting the cell therewith. 
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14. The method of claim 13, wherein said agent comprises 
a polynucleotide. 
15. The method of claim 13, wherein said agent comprises 
65 DNA. 
16. The method of claim 13, wherein said agent comprises 
a transgene. 
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17. The method of claim 16, wherein said agent is toxic for 
the cell. 
18. A method of delivering enhanced levels of an agent into 
a cell, the method comprising associating the agent with a 
polyamine cationic lipid according to compound (26) or a 5 
pharmaceutically acceptable salt thereof and effective in 
being recognized by a polyamine transport system in the cell. 
19. The method of claim 18, wherein said agent comprises 
a polynucleotide. 
20. The method of claim 18, wherein said agent comprises 10 
DNA. 
21. The method of claim 18, wherein said agent comprises 
a transgene. 
26 
24. The method of claim 23, wherein said agent comprises 
a polynucleotide. 
25. The method of claim 23, wherein said agent comprises 
DNA. 
26. The method of claim 23, wherein said agent comprises 
a transgene. 
27. The method of claim 23, wherein said agent is toxic for 
the cell. 
28. A method of treating a target cell having an upregulated 
polyamine transporter, the method comprising associating an 
agent with a polyamine cationic lipid according to compound 
(26) or a pharmaceutically acceptable salt thereof and con-
tacting the cell therewith. 
22. The method of claim 18, wherein said agent is toxic for 
the cell. 
29. The method of claim 28, wherein said agent comprises 
15 a polynucleotide. 
23. A method of delivering enhanced levels of an agent into 
target cells having an upregulated polyamine transporter, the 
target cells being among a population of normal cells, the 
method comprising associating the agent with a polyamine 
cationic lipid according to compound (26) or a pharmaceuti- 20 
cally acceptable salt thereof and contacting the cell popula-
tion therewith so as to preferentially deliver the polynucle-
otide into the target cells via the upregulated polyamine 
transporter system. 
30. The method of claim 28, wherein said agent comprises 
DNA. 
31. The method of claim 28, wherein said agent comprises 
a transgene. 
32. The method of claim 28, wherein said agent is toxic for 
the cell. 
* * * * * 
